TERN - Terns Pharmaceuticals Inc

TERN - Terns Pharmaceuticals Inc

https://www.ternspharma.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

GlobeNewswire • 3 weeks, 3 days ago • score: 0.03

Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET ...

Terns ( TERN ) Q2 Net Loss Narrows 16%

Motley Fool • 1 month, 1 week ago • score: 0.33

Terns Pharmaceuticals ( NASDAQ:TERN ) , a clinical-stage biopharmaceutical company developing therapies for chronic myeloid leukemia ( CML ) and metabolic diseases, released its second quarter results on August 5, 2025. The most notable news was continued progress in its two lead clinical ...

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

GlobeNewswire • 2 months, 3 weeks ago • score: 0.06

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study. topline data were presented in September ...

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

GlobeNewswire • 4 months ago • score: 0.10

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations ...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( C ) ( 4 )

GlobeNewswire • 4 months, 1 week ago • score: 0.22

FOSTER CITY, Calif., May 02, 2025 ( GLOBE NEWSWIRE ) -- Terns Pharmaceuticals, Inc. ( "Terns" or the "Company" ) ( Nasdaq: TERN ) , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, ...

Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals ( TERN ) Looks Ripe for a Turnaround

Zacks Commentary • 5 months, 1 week ago • score: 0.24

Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...

Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals ( TERN )

Zacks Commentary • 5 months, 1 week ago • score: 0.22

Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

All You Need to Know About Terns Pharmaceuticals ( TERN ) Rating Upgrade to Buy

Zacks Commentary • 5 months, 2 weeks ago • score: 0.33

Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street

Motley Fool • 6 months ago • score: 0.30

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other chronic liver diseases. The company is headquartered in Foster City, California.

52W High

$11.40

52W Low

$1.87

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

-0.05

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.80

EV/Revenue (<3 favorable)

337.47

P/S (TTM) (<3 favorable)

302.64

P/B (<3 favorable)

2.07

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.30%

Institutions (25–75% balanced)

99.10%

Shares Outstanding

87,511,000

Float

57,156,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,000,000

Gross Profit (TTM)

1,000,000

EPS (TTM)

-1.03

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.35%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.4075

Previous

0.4461

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025